Small molecules are pharmacological tools of considerable value in dissecting complex biological processes and identifying potential therapeutic interventions.
Introduction
Mitochondrial autophagy, known as mitophagy, governs the elimination of dysfunctional or superfluous mitochondria and is therefore fundamental to both mitochondrial and cellular homeostasis. 1 Impaired mitophagy may lead to an accumulation of damaged organelles within cells, underlying the pathogenesis of a number of chronic conditions including cancer, cardiovascular and liver diseases and neurodegeneration, particularly Parkinson's disease (PD). 2 Mitophagy operates via a number of distinct but interconnected mechanisms that can be generally classified as ubiquitin (Ub) dependent and independent pathways. . 5, 6 Once localized on mitochondria, Parkin acts in concert with PINK1 to amplify the initial signal by decorating mitochondria with Ub chains, which are sequentially phosphorylated by PINK1 (Figure 1c) . 6 Besides Parkin, other Ub ligases, such as SMURF1 7 and Gp78 8 , have been reported to contribute to the mitochondrial priming.
The accumulation of pSer 65 -Ub chains on the OMM triggers the recruitment of the autophagy receptors optineurin (OPTN) and nuclear dot protein 52 (NDP52), which promote the biogenesis of phagophores in close proximity to mitochondria by recruiting the autophagy-initiating factors ULK1 (unc-51 like autophagy activating kinase 1), DFCP1 (Double FYVE-domain containing protein 1) and WIPI1 (WD repeat domain, phosphoinositide interacting 1). 6 Moreover, OPTN and NDP52 act as molecular adaptors anchoring Ub-labelled mitochondria into autophagosomes by interacting directly with LC3 through their LC3-interacting regions (LIR) (Figure1b, c).
In addition to Ub-driven mitophagy, the OMM-localized mitophagy receptors BNIP3
(BCL2/adenovirus E1B 19 kDa protein-interacting protein 3), 10 NIX1/BNIP3L, 9 and FUNDC1 (FUN14 domain containing 1) 11 target mitochondria to autophagosomes independently of mitochondrial ubiquitination by interacting directly with LC3 and GABARAP (GABA A receptor associated protein) through typical or atypical LIR motifs (Figure 2a) . NIX1 was originally identified as a key mediator of mitochondrial removal during erythrocyte maturation, 12 but recently shown to be involved in ΔΨ m loss-induced mitophagy. 9 The expression of both NIX1 and the related BNIP3 is partially under the control of HIF-1 (hypoxia-inducible factor 1) and their up-regulation during hypoxia promotes the clearance of damaged mitochondria. 14, 15 BNIP3 along with FUNDC-1 are considered the main mediators of hypoxia-induced mitophagy. 11, 14 In contrast to NIX1
and BNIP3, the expression of FUNDC1 is not altered significantly during hypoxic or mitochondrial depolarization events, but instead its activity relies heavily on posttranslational modifications. 16 Under basal conditions, the interaction between LC3
and FUNDC1 is suppressed by the phosphorylation of the latter at multiple sites that are located close to its LIR domain. Upon hypoxia or ΔΨ m collapse however, the dephosphorylation of FUNDC1 at Ser 13 by the Ser/Thr phosphatase PGAM5
(Phosphoglycerate mutase family member 5) enhances its binding affinity for LC3
and facilitates the anchoring of mitochondria into autophagosomes (Figure 2b ). and plethora of off-target effects, such agents are widely used in regulatory and mechanistic cell biology studies due to the lack of more suitable chemical tools.
There is therefore a need to devise novel pharmacological approaches to manipulate the process and develop agents to activate mitophagy without perturbing the organelle as dramatically as most current inducers do. Besides their potential therapeutic utility in conditions associated with mitophagy defects, such agents would also serve as invaluable chemical probes to corroborate the core pathways of the process and unveil regulatory mechanisms and events that occur independently from the respiratory collapse. To delineate the current state of the field and highlight recent advances, we provide a critical appraisal of the chemical tools currently used to modulate mitophagy in addition to focusing on the most recent and promising approaches that pave the way for a better understanding of the process and leave hope for its future therapeutic exploitation.
H + Ionophores
Amongst the inducers of mitophagy identified to date, proton (H + ) ionophores, hereafter referred to as protonophores, are employed widely in cell biology studies.
Protonophores are weakly acidic lipophilic compounds capable of transporting H + across the inner mitochondrial membrane (IMM), thereby depleting the electrochemical proton gradient and uncoupling oxidative phosphorylation from the electron transport chain (ETC). 18 As a result of the extensive H + leak mediated by such agents, mitochondria are targeted for degradation, while the rate of oxygen consumption is increased in an effort to restore the diminished ATP generation, making protonophores valuable tools for the study of both mitochondrial autophagy and bioenergetics.
The phenylhydrazones carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and carbonyl cyanide-p-(trifluoromethoxy)phenylhydrazone (FCCP) and to a lesser extent the 2,4-dinitrophenol (DNP) have been extensively employed to probe the underlying mechanisms of mitophagy and characterize the biological pathways involved in this process ( Table 1) . 6, [19] [20] [21] CCCP in particular was one of the first agents reported to induce mitophagy and was successfully applied to unveil the involvement of the PDassociated protein Parkin in the regulation of this process.
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Despite their widespread use, protonophores have several limitations as mitophagystimulating chemical probes (Figure 1a) . In particular, their effects on mitochondria do not resemble naturally occurring conditions, being largely detrimental and leading eventually to mitochondrial failure. 22 Furthermore, they affect the entire mitochondrial population rather than a specific subgroup and can even lead to the complete elimination of mitochondria from cells after longer treatments. 20 Moreover, traditional protonophores are not specific for mitochondria and have protonophoric activity on other membranes, particularly the plasma membrane. 23 As a result, they mediate a variety of off-target effects, including disruption of the microtubule cytoskeleton 24 , inhibition of lysosomal activity 25 and activation of ion channels, 26 which leads to relatively high levels of toxicity and a narrow therapeutic window. Notably, FCCP is cytotoxic, even at concentrations that are not high enough to dissipate ΔΨ m and thus induce mitophagy. 27 contrast to FCCP, BAM15 exhibits high selectivity for the IMM and does not depolarize the plasma membrane or cause mitochondrial failure at high concentrations. However, its mitophagy-inducing potential is not fully evaluated yet and further work is therefore required to assess its suitability in this context.
Mitochondrial toxins
Similarly to protonophores, various toxins and respiration inhibitors activate PINK1-mediated mitophagy following dissipation of the ΔΨ m (Figure 1a) . A representative example is valinomycin, a highly specific potassium (K + ) ionophore that owing to its high lipophilicity, is able to transport K + ions across the IMM by masking their charge through a reversible interaction ( Table 1) . 29 The resulting accumulation of K + inside the mitochondrion eliminates the electrical potential and activates the PINK1-Parkin pathway without altering the pH gradient (Figure 1a, b) .
In addition to valinomycin, the ionophore salinomycin has been reported to induce mitophagy by interfering with mitochondrial K + homeostasis ( Table 1) . 30 However, its mode of action is distinct to that of valinomycin and instead of depolarizing the IMM, salinomycin induces its transient hyperpolarization. 30, 31 In contrast to valinomycin, salinomycin increases the efflux of K + from the mitochondrion by catalyzing their electroneutral exchange against protons and subsequently modifies the pH gradient across the IMM. 31 The acidification of the mitochondrial matrix impairs mitochondrial respiration and thus, limits the generation of ATP, eventually leading to mitochondrial failure and activation of the mitochondrial removal process. 30, 31 Another example is the antibiotic antimycin A that elicits a mitochondria-targeted autophagic response by inhibiting the respiratory complex III and leading to increased levels of reactive oxygen species (ROS) ( Table 1) . 32 Compared to protonophores and other mitochondrial toxins, antimycin A causes a relatively limited decrease in ΔΨ m that is rapidly balanced by the reverse hydrolysis activity of the F 1 Fo-ATPsynthase. 33 For that reason, it is often used in combination with oligomycin (Table 1) , which prevents this compensatory mechanism by inhibiting the F 1 FoATPsynthase and thus facilitates a more intense depolarization. 6 The activation of mitophagy by antimycin A and oligomycin is generally considered more relevant to naturally-occurring conditions, since both inhibitors are relatively selective for their targets and mediate fewer toxic effects, resulting in subtler mitochondrial damage. 6, 29 Similarly to antimycin A, a diverse range of chemicals, including sodium selenite, diquat, retigeric acid B and paraquat have been reported to trigger mitophagy in response to elevated levels of oxidative stress ( Table 1) . 4, 20, [35] [36] [37] 
Parkinsonian toxins
The pesticide paraquat, which is another well-studied mitochondrial toxin, activates mitophagy via excessive complex I-dependent superoxide generation. 4, 20 Similarly to Table 1) . [40] [41] [42] Rotenone in particular causes a relatively mild mitochondrial depolarization, which is inadequate to induce PINK1-mediated mitophagy in primary neurons or neuroblastoma cells. 41 Rotenone, as well as 6-OHDA (and so does Staurosporine) activate the process by promoting the externalization of cardiolipin, which recruits the autophagic machinery via a direct interaction with LC3 ( Figure 2c ). Moreover, 6-OHDA and MPP + were both found to promote the phosphorylation and mitochondrial accumulation of ERK2 (extracellular signal-regulated protein kinase 2), an event that drives mitochondria into autophagosomes and facilitates their degradation. 40, 43 The identification of divergent mitophagic pathways in neurons, which are exploited by the parkinsonian toxins and others, such as the apoptotic agent Staurosporin, suggest that the PINK1-Parkin pathway might be not the primary mechanism of neuronal mitochondrial quality control. 41 In fact, neurons exhibit a poor response to FCCP/CCCP-induced dissipation of ΔΨ m compared to HeLa and other non-neuronal cell lines, as evidenced by the delayed translocation of Parkin. 44 Parkinsonian toxins may therefore represent preferential chemical tools to stimulate mitophagy in neurons and investigate the underlying regulatory mechanisms.
Modulators of PINK1-Parkin activity
Ample evidence from the literature suggests that the integrity of the PINK1-Parkin pathway is essential for mitochondrial recycling and function. 45 Mutations in PINK1
and Parkin that affect their catalytic activities can lead to impaired mitophagy and underlie rare forms of early-onset PD. Despite the recent advances and scientific excitement around this pathway, efforts to pharmacologically modulate it remain
limited.
An unconventional but promising strategy to enhance PINK1-mediated mitophagy is based on the identification of N Table 1) . 46 Although still at an early stage, preliminary results suggest that this approach has great potential to restore mitophagy in conditions associated with loss-of-function PINK1 mutations. However, kinetin does not affect the stabilization of PINK1 under resting conditions and thus, an external stimulus, such as CCCP, is required to initiate mitophagy, which restricts its application as a mitophagy-stimulating chemical tool.
An alternative and rather interesting approach to augment the activity of the PINK1-Parkin pathway resides in the inhibition of the tumor suppressor p53, which regulates the expression levels of PARK2. 47 On the other hand, Parkin represses the transcription of p53 by physically interacting with its promoter region 48, 49 -although this appears to depend on cell or tissue type. 47 This suggests that at least in some particular cell types a feedback loop between Parkin and p53 exists that may play a regulatory role in mitophagy. In support of this notion, p53 may suppress mitophagy by directly interacting with Parkin and halting its translocation to mitochondria, whilst pharmacological intervention with pifithrin-α, a small molecule inhibitor of p53, restored mitochondrial clearance in a p53-dependent manner (Figure 3b) . 50 In a different study, pifithrin-α was shown to promote mitophagy and ameliorate mitochondrial dysfunction in type I and II mouse models of diabetes. 51 Interestingly, elevated levels of p53 exist in the brains of animal models and human cases of PD, a condition strongly associated with impaired mitochondrial function and quality control, 52, 53 while inhibition of p53 by pifithrin-α reduces dopaminergic neuron death and protects against MPTP neurotoxicity in vivo. 54 Moreover, p53 -/-mice have higher levels of basal mitophagy compared to their wild type counterparts, leading to increased resistance against doxorubicin-induced mitochondrial injury. 50 However, p53 is a master regulator of several cellular processes and as a result, its pharmacological targeting may impinge diverse biological effects beyond the induction of mitophagy. Therefore, despite the emerging link between p53 and Parkin-mediated mitophagy, the specificity in targeting mitophagy via this approach is questionable.
In addition to p53 inhibitors, a diverse group of small molecule modulators of PARK2 transcription was recently identified through high-throughput screening (HTS) of bioactive compounds using a Firefly/NanoLuc luciferase coincidence reporter system. 55 These include modulators of epigenetic mechanisms, such as histone deacetylase and bromodomain inhibitors, and small molecule inhibitors of cholesterol biosynthesis, such as mevastatin and fluvastatin. 56 Interestingly, the JNK inhibitor SR3306, another promising lead identified in the same study, seems to enhance mitochondrial quality control in a cell-based model of mitochondrial stress induced by the accumulation of misfolded ΔOTC (truncated ornithine transcarbamylase).
Recently, novel molecular routes to enhance PINK1-Parkin mitophagy without interfering directly with the pathway were described. A good example is the 18-kDa translocator protein (TSPO), which regulates mitophagy downstream of the PINK1- 
Iron chelators
The development of sensitive phenotypic assays for monitoring alterations in the levels of cellular mitophagy enabled the identification of several modulators of the process. 63, 64 In particular, a chemical screen utilizing a tandem mCherry-GFP tag anchored on the OMM, yielded the iron chelator deferiprone (DFP) as a novel inducer of mitophagy ( Table 1 and Figure 5b) . 63 DFP was shown to promote mitochondrial turnover via an iron depletion-dependent mechanism without causing a ΔΨ m collapse. Interestingly, DFP retains its activity in cells devoid of a fully functional PINK1-Parkin pathway and this has prompted its use as a chemical tool to assess
Parkin-independent mitophagy in recent studies. 65, 66 Intriguingly, 1,10'-phenanthroline (Phen), another compound with siderophore-like properties, was identified as a "hit" in a chemical screen for mitophagy activators ( Table 1) . 64 In contrast to DFP, Phen mediates a collapse of ΔΨ m , which is followed by a Drp1-dependent mitochondrial fragmentation and induction of mitophagy.
Consistently with aspects of the latter study, Phen and the structurally distinct iron chelator, cicloprox olamine (Table 1) , were reported to trigger mitophagy in response to mitochondrial depolarization in mammalian cells and nematodes. 67 However, Phen is unable to exert similar effects in neuronal-like SH-SY5Y cells, suggesting that its mitophagic activity might be cell type dependent. 68 In addition, the structurally similar siderophore 2'2-bipyridyl was shown to extend lifespan in C. elegans by inducing a mitophagic response that was dependent on PINK1 as well as PBR-1 and DCT-1, the C. elegans homologues of Parkin and NIX1/BNIP3 respectively ( Table 1 and Figure 5b ).
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Although pharmacologically induced iron depletion appears to stimulate mitophagy, further studies are required to elucidate the underlying mechanisms given the contradictory observations. With the exception of DFP, iron chelators trigger mitophagy by collapsing ΔΨ m , which points towards mitochondrial toxicity.
Nonetheless, a metabolic switch from oxidative phosphorylation to glycolysis is required for the induction of mitophagy by iron depletion, 63 which may indicate respiratory injury and thus, restrict the therapeutic application of such agents particularly in neurodegenerative conditions, as neurons rely heavily on oxidative phosphorylation.
SIRT1 activators
Nicotinamide (NAM) was recently reported to promote mitophagy without perturbing mitochondrial function or collapsing the ΔΨ m ( Table 1) . 70 On the contrary, primary human fibroblasts treated with NAM exhibit elevated levels of resting ΔΨ m -however this is accompanied by a fragmentation of the mitochondrial network. 71 The effects of NAM are attributed to the activation of SIRT1 (silent information regulator T1), an NAD + -dependent deacetylase involved in the regulation of longevity. 71 By acting as its biosynthetic precursor, NAM increases the cellular availability of NAD + , which in turn activates SIRT1 and promotes mitochondrial clearance.
Interestingly, other SIRT1 activators, including the natural products resveratrol and fisetin and the synthetic small molecule SRT1720 ( 
Nrf2 inducers and the anterograde regulation of cell mitophagy
The transcription factor nuclear factor E2-related factor 2 (Nrf2, Gene ID: 4780) has been proposed as an attractive target to enhance mitochondrial function and health.
Genetic or pharmacological augmentation of Nrf2 activity has a number of beneficial effects on mitochondria. (Figure 4) . 86 This compound, which we named p62/SQSTM1-mediated mitophagy inducer (PMI), increases the expression of p62/SQSTM1 and drives mitochondria into autophagy without disrupting the ΔΨ m (Figure 5a) . 85 Nrf2 and p62/SQSTM1 are both indispensable to the mitophagic pathway exploited by PMI, as delivery of mitochondria to autophagosomes is abolished in Nrf2 -/-or p62 -/-cells. Keap1-KD cells. 87 Moreover, PMI does not alter mitochondrial morphology and in contrast to common mitophagy inducers, the activation of mitophagy is not accompanied by mitochondrial swelling or fragmentation. 85 PMI has a distinct mode of action compared to traditional Nrf2 inducers, such as the isothiocyanate sulforaphane (Figure 4) . 85, 88 Typical Nrf2 activators are electrophiles that react with sensor cysteines on Keap1, inducing an irreversible conformational change that halts the ubiquitination of Nrf2. 89 However, the vast majority of these compounds are capable of reacting with a range of cysteine-containing redox sensitive proteins, giving rise to a host of off-target effects. 86 The activation of general autophagy by sulforaphane is an example of great relevance as it occurs via a ROSdependent mechanism and independently of its effects on Nrf2. 90 On the other hand, PMI promotes a targeted autophagic degradation of mitochondria without affecting general autophagy. 85 Notably, our preliminary results suggest that sulforaphane does not mediate similar effects on mitophagy, despite activating Nrf2 and up-regulating the expression of p62/SQSTM1. These differences further highlight the potential utility of PMI compared to sulforaphane and related electrophilic Nrf2 inducers and hint at the therapeutic potential of such compounds.
Pharmacological inhibitors of mitophagy
The most widely adopted protocol to block the process of mitophagy in vitro resides on the pharmacological inhibition of lysosomal acidification, using the V-ATPase (Vacuolar-type H + -ATPase) inhibitor bafilomycin A1 or the lysomotropic agents chloroquine and hydroxychloroquine (for a review see 91 ). In addition, compounds that suppress general autophagy by inhibiting the formation of autophagosomes have also been used to halt mitophagy, with the class III PI3K inhibitor 3-methyladenine being the most prominent example. Although these approaches are particularly effective at inhibiting mitophagy, they also affect other autophagic and lysosomal processes and are therefore largely unspecific.
Novel strategies to inhibit mitophagy in a more specific manner have been described, however their application to date has been limited. conjugated to a cell-permeating TAT peptide-derived sequence. 95 Mechanistically, P110 appears to inhibit Drp1 by impairing its enzymatic activity and blocking its translocation to mitochondria by selectively disrupting its PPI with the OMM-localized protein Fis1. Interestingly, P110 does not inhibit mitochondrial fission under resting conditions, but instead prevents the abnormal mitochondrial fragmentation induced by several mitochondrial stressors, including FCCP and MPP + . However, to our knowledge no studies describing the effects of P110 on mitophagy have been reported to date and its potential as a negative modulator of the process remains to be determined.
Concluding Remarks
Restoring the ability of cells to efficiently eliminate damaged or dysfunctional mitochondria is likely to be pivotal to the prevention of a wide range of diseases.
Equally paramount is the need to identify novel chemical probes that can be used to understand the process of mitophagy, and correct defects. Notably, the increased understanding of the molecular determinants governing mitophagy has not been mirrored by the development of suitable chemical probes with potential therapeutic uses.
Both clinicians and scientists engaged in characterizing the mechanistic aspects of mitophagy will greatly benefit from improved pharmacological approaches to induce and control this mechanism of cellular quality control more selectively. From the recent literature it is notable that the original protocols based upon acute mitochondrial depolarization induced by non-specific agents (e.g. FCCP/CCCP), have been gradually refined into "milder" approaches (e.g. Antimycin A/Oligomycin) aimed at promoting mitophagy in a more physiologically compliant manner. Although uncoupling agents have been instrumental in understanding how depolarization of the mitochondrion triggers regulatory pathways leading to removal of the disposable organelles, the need for alternative approaches that are translatable into an in vivo context is now a priority.
Specifically, the latest advancements in the field demonstrated that the process of mitophagy operates beyond the context of acute mitochondrial stress, such as during resting physiology, maintaining the integrity of the mitochondrial network and contributing to the preservation of cellular homeostasis. In particular, subtle changes in mitochondrial redox status 96 such as increases mitochondrial respiratory activity and energy production 97 were recently shown to activate mitophagy, adding another layer of complexity to the regulation of the process. Additionally, the accumulation of misfolded proteins can trigger PINK1-Parkin mediated mitophagy in energetically healthy mitochondria, suggesting that this pathway can also operate independently of respiratory collapse in response to other cues. 98 Mitophagy is therefore likely to be part of a finely tuned mechanism that integrates both anabolic and catabolic mechanisms catalyzing the events of mitohormesis. Agents that modulate cellular adaptive responses to stressors or toxins have the potential to further progress our understanding of the underpinning pathways of mitophagy. Notably, stimulation of mitophagy is proven to occur in response to the activation of Nrf2, a transcription factor often referred to as the master regulator of the antioxidant response. 85 This highlights another scenario for mitophagy as a process integrated and governed by pathways dictating cellular resilience to impaired physiology, therefore widening the prospects for subsequent pharmacological validation and intervention in this process.
We are therefore optimistic that the review of the pharmacological modulation of mitophagy provided here may draw attention to the need for new, specific modulators of mitophagy and facilitate discussion within the field about the best ways to identify and characterize the next generation of chemical probes and therapeutic agents that target this intriguing cellular process. reports also on the iron chelators, which apparently involve more than one mechanism to complete the autophagic removal of mitochondria (ii). 
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